| Literature DB >> 34522630 |
Ashandree Reddy1,2, Nadine Rapiti2,3, Verena Gounden1,2.
Abstract
BACKGROUND: The International Myeloma Working Group and College of American Pathologists recommend a 24-h urine collection to determine the Bence Jones protein (BJP) excretion level for monitoring treatment response in patients with multiple myeloma (MM). There are several issues related to sample collection and the method is prone to inaccuracy.Entities:
Keywords: Bence Jones protein; estimated 24-h Bence Jones protein; multiple myeloma; random urine
Year: 2021 PMID: 34522630 PMCID: PMC8424753 DOI: 10.4102/ajlm.v10i1.1228
Source DB: PubMed Journal: Afr J Lab Med ISSN: 2225-2002
Comparison of the advantages and disadvantages of random and 24-h urine collection for Bence Jones protein.
| Method | Advantages | Disadvantages |
|---|---|---|
| Random urine |
Easy to obtain Rapid transfer to the laboratory which avoids potential degradation Collected any time of day No need for the patient to store sample and transport to the laboratory |
Synthesis and release of Bence Jones protein may be variable throughout the day |
| 24-h urine |
Defines Bence Jones protein excretion over the entire 24 h Directly relates to published data on 24-h Bence Jones protein excretion |
Inconvenient and complex for patient collection, storage and transport to the hospital Frequent incomplete collections Total urinary protein varies with urine volume |
Source: See full reference list of the article Beetham R, Cattell WR. Proteinuria: Pathophysiology, significance and recommendation for measurement in clinical practice. Ann Clin Biochem. 1993;30(5):425–434. https://doi.org/10.1177/000456329303000502, for more information.
Patient characteristics including demographics, immunotyping and relevant laboratory results obtained from King Edward Hospital, Durban, South Africa, April 2016 – March 2018.
| No. | Age | Gender | Serum immunofixation electrophoresis | Urine immunofixation electrophoresis | Bence Jones protein (mg/24 h) | E1 (mg/24 h) | E2 (mg/24 h) | Total serum calcium (mmol/L) | Albumin (g/L) | Estimated glomerular filtration rate (mL/min/1.73m2) | Total protein (g/L) | Haemoglobin (g/dL) | Serum free light chain ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 58 | F | IgA K and free K | Free K | 2520 | 1256.28 | 949.52 | 2.65 | 42 | 17 | 81 | 5.2 | ND |
| 2 | 74 | M | IgG K and free K | n/a | 1080 | 1286.17 | 1705.47 | 2.03 | 22 | 15 | 98 | 5.9 | ND |
| 3 | 57 | F | IgG K and free K | Free K | 3430 | 1636.36 | 1562.27 | 1.89 | 17 | > 60 | 41 | 5.7 | ND |
| 4 | 61 | M | IgG K and free K | Free K | 690 | 899.60 | 795.25 | 2.06 | 16 | > 60 | 108 | 7.7 | ND |
| 5 | 59 | F | IgG K and free K | Free K | < 0.15 | 350.82 | 437.27 | 2.20 | 26 | 24 | 82 | 9.3 | ND |
| 6 | 54 | F | IgA K and free K | IgA K and free K | 6800 | 4712.54 | 4499.15 | 1.70 | 20 | 7 | 86 | 7.7 | ND |
| 7 | 59 | M | IgA K | Free K | < 0.15 | 460.51 | 447.80 | 2.17 | 29 | 36 | 95 | 8.6 | 4.73 |
| 8 | 58 | M | IgG K | IgG K | 380 | 597.97 | 1046.63 | 3.18 | 20 | 18 | 153 | 6.4 | ND |
| 9 | 63 | M | IgG K | n/a | < 0.15 | 397.14 | 575.76 | 2.65 | 28 | 37 | 100 | 8.8 | ND |
| 10 | 47 | M | Free L | Free L | 14 400 | 7142.86 | 9597.71 | 3.36 | 34 | 16 | 73 | 5.9 | ND |
| 11 | 56 | F | Free L | Free L | 8580 | 5137.11 | 5790.04 | 2.60 | 40 | 48 | 73 | 13.3 | 0.01 |
| 12 | 53 | F | IgG L and free L | IgG L and free L | 380 | 393.55 | 412.26 | 2.20 | 35 | 19 | 83 | 9.1 | ND |
| 13 | 65 | M | Free K | Free K | 2660 | 1917.79 | 2034.39 | 2.28 | 40 | > 60 | 67 | 7.9 | 1.76 |
| 14 | 57 | F | IgG K | IgG K and free K | 250 | 0.00 | 0.00 | 1.90 | 19 | 9 | 96 | 7.4 | ND |
| 15 | 47 | F | IgA K | IgA K and free K | 2480 | 4481.63 | 3743.86 | 3.49 | 16 | 8 | 140 | 6.7 | 102.23 |
| 16 | 49 | M | IgA K | IgA K and free K | 680 | 211.84 | 269.67 | 2.04 | 21 | 50 | 109 | 9.2 | 0.76 |
| 17 | 49 | F | IgA L | Free L | 1200 | 1628.22 | 1403.36 | 2.60 | 21 | 23 | 118 | 6 | ND |
| 18 | 55 | M | Free L | Free L | 3600 | 956.73 | 1945.23 | 2.19 | 38 | > 60 | 65 | 10.3 | 0.01 |
| 19 | 56 | F | Free K | Free K | 6150 | 7087.63 | 6484.76 | 2.59 | 37 | 10 | 72 | 6.6 | leaked |
| Mean (s.d.) | 2500 | 2362.00 | 2629.00 | 2.4 (0.5) | 27.4 (8.9) | 10.0 | 91.6 (25.9) | 7.8 (1.9) | - | ||||
Reference ranges: serum free light chain 0.26–1.65, calcium 2.15 mmol/L – 2.55 mmol/L, albumin 35 g/L – 52 g/L.
F, female; K, kappa; L, lambda; M, male; ND, not done; s.d., standard deviation; Ig, immunoglobulin; n/a, not applicable.
, Patient of Indian decent;
, The three patients are those with samples before and after treatment. Only their initial samples are included in this table.
Summary data of the patient characteristics, the mean or median for the measured 24-h Bence Jones protein and the Estimated Bence Jones protein for the 19 patients, between April 2016 and March 2018, Durban, South Africa.
| Parameter | Mean ± s.d. | Median | Range |
|---|---|---|---|
| Age (years) | 55.8 ± 6.6 | - | - |
| Body mass index (m2/kg) | 27.5 ± 5.4 | - | - |
| Measured 24-h Bence Jones protein (mg/24 h) | - | 2500 | 250–14 400 |
| E1 (mg/24 h) | - | 2362 | 211–7143 |
| E2 (mg/24 h) | - | 2629 | 267–9597 |
Note: E1 refers to Estimated 24-h BJP (mg/24 h) = Urine BJP/Creatinine ratio (mg/mmol) ´10 and E2 refers to Estimated 24-h BJP (mg/24 h) = Urine BJP/Creatinine ratio (mg/mmol)´ 15 mg/kg for women or × 20 mg/kg for men (convert mg/kg to mmol/kg by multiplying 0.00884).[13]
N = 19.
s.d., standard deviation.
Estimated equations (E1 and E2) and 24-h Bence Jones protein categorised according to gender between April 2016 and March 2018, Durban, South Africa.
| Patient no. | E1 (mg/24-h) | E2 (mg/24-h) | 24-h Bence Jones protein (mg/24-h) |
|---|---|---|---|
|
| |||
| 1 | 1256.0 | 949.5 | 2520.00 |
| 2 | 1636.4 | 1562.3 | 3430.00 |
| 3 | 350.8 | 437.3 | < 0.15 |
| 4 | 4712.5 | 4499.2 | 6800.00 |
| 5 | 5137.1 | 5790.0 | 8580.00 |
| 6 | 393.6 | 412.3 | 380.00 |
| 7 | 0.0 | 0.0 | 250.00 |
| 8 | 4481.6 | 3743.9 | 2480.00 |
| 9 | 1628.2 | 1403.4 | 1200.00 |
| 10 | 7087.6 | 6484.8 | 6150.00 |
| Mean | 2668.0 | 2528.2 | 3179.00 |
|
| |||
| 1 | 1286.2 | 1705.5 | 1080.00 |
| 2 | 899.6 | 795.3 | 690.00 |
| 3 | 460.5 | 447.8 | < 0.15 |
| 4 | 598.0 | 1046.6 | 380.00 |
| 5 | 397.1 | 575.8 | < 0.15 |
| 6 | 7142.9 | 9597.7 | 14400.00 |
| 7 | 1917.8 | 2034.4 | 2660.00 |
| 8 | 211.8 | 269.7 | 680.00 |
| 9 | 956.7 | 1945.2 | 3600.00 |
| Mean | 1541.2 | 2046.4 | 2610.00 |
Comparison of 24-h Bence Jones protein with the estimate equations (E1 and E2) in three paired patient samples before and after treatment over the April 2016 – March 2018 period in Durban, South Africa, together with their response classification.
| Patient | Sample | Bence Jones protein (mg/24 h) | E1 (mg/24 h) | E2 (mg/24 h) | International Myeloma Working Group response criteria[ |
|---|---|---|---|---|---|
| 1 | A | 8580 | 5137.1 | 5790.0 | - |
| B | 9240 | 5286.4 | 5888.2 | - | |
| Difference (%) | 7.1 | 2.8 | 1.6 | Stable disease | |
| 2 | A | 680 | 211.8 | 269.7 | - |
| B | 290 | 297.0 | 383.4 | - | |
| Difference (%) | 57.4 | 40.0 | 42.0 | Stable disease | |
| 3 | A | 2480 | 4481.6 | 3743.9 | - |
| B | 1610 | 549.5 | 728.6 | - | |
| Difference (%) | 35 | 88.0 | 81.0 | Stable disease |
Note: International Myeloma Working Group response criteria were reviewed by comparing percentage difference before treatment, Sample A, and after treatment, Sample B.
FIGURE 1Regression analysis of measured 24hr Bence Jones protein excretion versus E1 estimation for 24-h Bence Jones protein during the period April 2016 – March 2018 in Durban, South Africa.
FIGURE 2Regression analysis of measured 24-h Bence Jones protein excretion versus E2 estimation for 24-h Bence Jones protein, during the period April 2016 – March 2018 in Durban, South Africa.